0VH Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€478.78K
Enterprise Value€0.86
Total Cash (Recent Filing)€13.22K
Total Debt (Recent Filing)€292.14K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding38,441,680
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Transdermal Product PlatformOvation’s focus on topical products supported by proprietary transdermal delivery approaches gives it a defined product platform rather than a purely undifferentiated offering. If formulation and delivery benefits translate into customer adoption, this technology base can support product development and commercial expansion over time.
Improving Cash BurnThe improvement in cash burn indicates some cost containment and better operating discipline compared with earlier periods. Although the company remains cash-flow negative, continued control of outflows could extend financial runway and reduce the pace at which external funding is required.
Prior Revenue ReboundThe substantial 2024 revenue rebound demonstrates that the business has shown an ability to recover sales after weaker periods. While the subsequent decline limits confidence in durability, evidence of prior top-line recovery provides a base for rebuilding commercial momentum if product demand improves.
Bears Say
Persistent Unprofitability And Unstable MarginsOngoing net losses and recurring negative gross profit show that the current business model has not yet established dependable unit economics. The reversal from positive gross profit to negative results also indicates limited operating leverage, making sustained profitability difficult without stronger revenue or cost improvements.
Negative Equity And Recapitalization RiskNegative equity is a significant balance-sheet weakness because liabilities exceed recorded assets and reduce financial flexibility. Combined with existing debt and continuing losses, this condition raises the likelihood that future operations may require recapitalization, potentially creating dilution pressure for shareholders.
Dependence On External FinancingThe company does not currently generate enough cash from operations to fund itself, since both operating and free cash flow remain negative. Persistent funding needs can constrain investment in product commercialization, increase financing dependence, and make execution more vulnerable if capital is not available.
Ovation Science News
0VH FAQ
What was Ovation Science Inc’s price range in the past 12 months?
Ovation Science Inc lowest stock price was €0.01 and its highest was €0.02 in the past 12 months.
What is Ovation Science Inc’s market cap?
Ovation Science Inc’s market cap is €478.78K.
When is Ovation Science Inc’s upcoming earnings report date?
Ovation Science Inc’s upcoming earnings report date is Nov 30, 2026 which is in 73 days.
How were Ovation Science Inc’s earnings last quarter?
Ovation Science Inc released its earnings results on Aug 11, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Ovation Science Inc overvalued?
According to Wall Street analysts Ovation Science Inc’s price is currently Overvalued.
Does Ovation Science Inc pay dividends?
Ovation Science Inc does not currently pay dividends.
What is Ovation Science Inc’s EPS estimate?
Ovation Science Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ovation Science Inc have?
Ovation Science Inc has 38,441,680 shares outstanding.
What happened to Ovation Science Inc’s price movement after its last earnings report?
Ovation Science Inc reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ovation Science Inc?
Currently, no hedge funds are holding shares in DE:0VH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ovation Science Inc
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and transdermal skincare formulations. This system integrates hemp seed oil and cannabis, underpinning the company's Ovation and BASKiN brands. Additionally, Ovation Science provides a diverse product portfolio including Invibe MD for CBD-infused health and wellness, ARLO CBD for skincare, and DermSafe for hand sanitizers. The company possesses sublicenses for its cannabis product lines and utilizes its Lighthouse initiative to engage with licensed dispensaries throughout the United States. Founded in 2017, Ovation Science Inc. is based in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Vext Science
―
BioNxt Solutions
―